ArticleVaccine2018
Evaluating the promise of recombinant transmissible vaccines.
Article in Vaccine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 23 citations in OpenAlex.
- Evaluating vectors for the design of a spillover-disrupting Lassa virus transmissible vaccine.PLoS computational biology · 2026Article
- Ecological vaccination: A strategy to prevent zoonotic spillover from bats.Science advances · 2026Article
- Research Progress of Microneedles in Vaccine Delivery.Current medicinal chemistry · 2026Review
- Optimizing the delivery of self-disseminating vaccines in fluctuating wildlife populations.PLoS neglected tropical diseases · 2023Article
- Inferring the disruption of rabies circulation in vampire bat populations using a betaherpesvirus-vectored transmissible vaccine.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- One step closer to a transmissible vaccine for rabies virus.PLoS biology · 2022Article
- Longitudinal deep sequencing informs vector selection and future deployment strategies for transmissible vaccines.PLoS biology · 2022Article
- Quantifying the effectiveness of betaherpesvirus-vectored transmissible vaccines.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Suppressing evolution in genetically engineered systems through repeated supplementation.Evolutionary applications · 2021Article
- Designing transmissible viral vaccines for evolutionary robustness and maximum efficiency.Virus evolution · 2021Article
- Epidemiology and biology of a herpesvirus in rabies endemic vampire bat populations.Nature communications · 2020Article
- Self-disseminating vaccines to suppress zoonoses.Nature ecology & evolution · 2020Review
- Fluorescent biomarkers demonstrate prospects for spreadable vaccines to control disease transmission in wild bats.Nature ecology & evolution · 2019Article
- Evolution and containment of transmissible recombinant vector vaccines.Evolutionary applications · 2019Article
- Recombinant vector vaccine evolution.PLoS computational biology · 2019Article
- Transmissible vaccines in heterogeneous populations: Implications for vaccine design.One health (Amsterdam, Netherlands) · 2019Article
- A little goes a long way: Weak vaccine transmission facilitates oral vaccination campaigns against zoonotic pathogens.PLoS neglected tropical diseases · 2019Article
- Transmissible vaccines whose dissemination rates vary through time, with applications to wildlife.Vaccine · 2019Article
- Controlling epidemics with transmissible vaccines.PloS one · 2018Article
- Recombinant transmissible vaccines will be intrinsically contained despite the ability to superinfect.Expert review of vaccinesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Transmissible vaccines have the potential to revolutionize infectious disease control by reducing the vaccination effort required to protect a population against a disease. Recent efforts to develop transmissible vaccines focus on recombinant transmissible vaccine designs (RTVs) because they pose reduced risk if intra-host evolution causes the vaccine to revert to its vector form. However, the shared antigenicity of the vaccine and vector may confer vaccine-immunity to hosts infected with the vector, thwarting the ability of the vaccine to spread through the population. We build a mathematical model to test whether a RTV can facilitate disease management in instances where reversion is likely to introduce the vector into the population or when the vector organism is already established in the host population, and the vector and vaccine share perfect cross-immunity. Our results show that a RTV can autonomously eradicate a pathogen, or protect a population from pathogen invasion, when cross-immunity between vaccine and vector is absent. If cross-immunity between vaccine and vector exists, however, our results show that a RTV can substantially reduce the vaccination effort necessary to control or eradicate a pathogen only when continuously augmented with direct manual vaccination. These results demonstrate that estimating the extent of cross-immunity between vector and vaccine is a critical step in RTV design, and that herpesvirus vectors showing facile reinfection and weak cross-immunity are promising.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.